What is Imaxio?
Imaxio operates as a specialized biotechnology firm dedicated to the field of immunology. The company's core strength lies in its proprietary IMX313 technology platform, which is instrumental in re-engineering antigens to enhance immunogenicity. This platform underpins a diverse pipeline that includes marketed products, such as a vaccine for human leptospirosis, alongside clinical-stage and preclinical-stage vaccine and immunotherapy candidates. Established in 2000 as a spin-off from the Medical Research Council and the University of Cambridge, Imaxio's strategic objective is to advance its internal R&D projects through Phase I and Phase II clinical trials before out-licensing them to biopharmaceutical partners for late-stage development and commercialization. The company actively seeks collaborations with entities aiming to improve the immune response for antigens that are otherwise poorly immunogenic.
How much funding has Imaxio raised?
Imaxio has raised a total of $11.9M across 3 funding rounds:
Unspecified
$4M
Grant
$7.2M
Grant
$772K
Unspecified (2012): $4M, investors not publicly disclosed
Grant (2013): $7.2M led by Jenner Institute
Grant (2014): $772K supported by Agence nationale de la recherche ANR
Key Investors in Imaxio
Jenner Institute
The Jenner Institute, a partnership between the University of Oxford and The Pirbright Institute, is a non-profit research and development entity focused on creating innovative vaccines against major global diseases for both humans and livestock. It specializes in translational research, rapidly advancing new vaccine approaches through early-stage clinical trials.
Agence nationale de la recherche ANR
The Agence nationale de la recherche (ANR) is the French national agency dedicated to funding project-based research across a wide spectrum of scientific disciplines. It supports initiatives focused on sustainable development and fosters national and international collaborations, playing a key role in financing scientific innovation.
What's next for Imaxio?
The recent major strategic investment positions Imaxio for accelerated growth and pipeline expansion. With a clear strategy to develop its R&D assets to mid-stage clinical trials and then partner for commercialization, the company is poised to leverage this capital to further its research and development initiatives. The focus on improving vaccine efficacy through its unique technology platform suggests a strong potential for future licensing deals and market penetration in the immunology and vaccine sectors. This funding round is a critical step in Imaxio's journey to bring novel immunotherapies and vaccines to market.
See full Imaxio company page
